American Century Companies Inc. Buys 60,548 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

American Century Companies Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 17.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 407,294 shares of the biotechnology company's stock after purchasing an additional 60,548 shares during the quarter. American Century Companies Inc. owned 0.67% of Ascendis Pharma A/S worth $56,072,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Rice Hall James & Associates LLC grew its stake in shares of Ascendis Pharma A/S by 2.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after acquiring an additional 3,274 shares in the last quarter. Nomura Asset Management Co. Ltd. grew its holdings in shares of Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock worth $2,688,000 after acquiring an additional 5,371 shares during the last quarter. Maven Securities LTD purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth about $7,466,000. Exome Asset Management LLC raised its holdings in shares of Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock worth $6,547,000 after acquiring an additional 23,849 shares in the last quarter. Finally, abrdn plc lifted its holdings in shares of Ascendis Pharma A/S by 18.3% during the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after buying an additional 28,967 shares during the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Cantor Fitzgerald upped their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Finally, UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $204.64.

Ascendis Pharma A/S Stock Performance

ASND traded down $3.26 on Friday, hitting $154.68. 289,067 shares of the company were exchanged, compared to its average volume of 465,825. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37. The firm has a fifty day simple moving average of $144.16 and a two-hundred day simple moving average of $137.34. The stock has a market capitalization of $9.39 billion, a PE ratio of -21.79 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. On average, equities analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.